Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says | WAPE

Newsbenzinga

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

Jun 11, 2026, 09:09 ET · Published

Article summary

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.

An excerpt from the original article.

Related companies

ARGXARGXView stock

Comments —

Comment

Loading comments…